Charles River Laboratories International Stock Earnings Reports

Key investor takeaways from Charles River Laboratories Q1 2026 earnings call: 1) Leadership and strategy — Birgit Girshick has been named CEO and introduced a refreshed strategic framework called "Pathway to Purpose," focused on modernizing operations, strengthening scientific capabilities (including NAMs and regulated testing), and deepening client-centricity. An Investor Day is planned for September with more detail. 2) Portfolio actions — Completed acquisitions (K.F. Cambodia assets; PathoQuest) to secure NHP supply and advance NAMs; completed divestiture of CDMO and Cell Solutions and expects sale of certain European discovery sites in May to sharpen focus on core competencies. 3) Cost and margin program — Management expects at least $100 million of incremental cost savings in 2026 (above 2025 levels) and >$300 million of cumulative annualized savings from prior actions; expects operating margin expansion of ~120–150 basis points in 2026, with most of the benefit in H2. 4) Q1 performance — Reported revenue $996M (+1.2% YoY) and organic revenue down 1.5% (in line with outlook); non-GAAP operating margin 16.3% (down 280 bps); non-GAAP EPS $2.06 (down 12%). Discrete Q1 margin headwinds included timing of NHP shipments, higher NHP sourcing/study starts, and elevated stock comp related to CEO transition. 5) Demand and backlog — DSA net book-to-bill was 1.04x, backlog modestly up to $1.92B; proposal volumes and bookings have improved (proposal growth high-single digits YoY; proposals up sequentially for three consecutive quarters), with biotech bookings notably stronger. Management is cautiously optimistic for a return to DSA organic growth in H2. 6) Guidance and capital allocation — Reaffirmed 2026 guidance: organic revenue decline of 0.5%–1.5% and non-GAAP EPS $10.80–$11.30 (5%–10% growth vs. 2025), with reported revenue lowered due to FX and divestitures. Management repurchased ~$200M of shares in Q1 under a $1B authorization and expects free cash flow $375M–$400M for 2026. 7) Q2 expectations — Sequential improvement expected: reported revenue down mid- to high-single digits (due to divestitures), organic revenue down low-single digits, and Q2 EPS expected to increase at least 30% sequentially from Q1 ($2.06) as discrete headwinds abate and divestiture benefits kick in. 8) Risks/notes — FX headwind from a stronger USD; NIH/government funding uncertainty modestly impacting some clients; early-stage biotech funding still mixed (larger/later-stage biotechs improving, earliest-stage remaining tepid); NAMs and AI are long-term tailwinds but will evolve gradually and require validation.